According to the CDC’s Behavioral Risk Factor Surveillance System 2013, nearly 71% of adults with atherosclerotic cardiovascular disease use aspirin regularly.
Prescribing low-dose aspirin for preventing secondary cardiovascular disease is well established, but its safety and efficacy in primary prevention remains open to debate.
Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.